ETN029
Based on 1 Customer Validation
ETN029 (MC339) is a selective DLL3 ligand. ETN029 labeled with 225Ac has dose-dependent cytotoxicity in SCLC, NEPC and metastatic melanoma cells and increases the phosphorylation of H2AX expression. ETN029 labeled with 177Lu shows rapid uptake persistent tumor retention and favorable tumor-to-kidney ratio. ETN029 can be used for cancers like SCLC and NEPC imaging and research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.91%
- CAS No.: 3066864-32-9
- Formule: C101H140N22O26S2
- Masse moléculaire:2142.45
-
Stockage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
ETN029 (MC339) binds human DLL3 with picomolar affinity and specificity, showing high cell binding and internalization in both SHP-77 and transgenic CT26.DLL3 cell lines, with minimal binding to DLL3-negative CT26.WT controls[3].
[225Ac]Ac-ETN029 exhibits dose-dependent cytotoxicity in SCLC, NEPC, and metastatic melanoma cell lines and increases the phosphorylation of H2AX, a marker for DNA double-strand breaks[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In CDX models (NCI-H69, SHP-77), a single dose of [225Ac]Ac-ETN029 (0.35-1.4 µCi) resulted in robust tumor regression and prolonged survival[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 3066864-32-9
-
Appearance Solid
-
Masse moléculaire 2142.45
-
Formule C101H140N22O26S2
-
Color White to light yellow
-
SMILES
CC(N[C@@H](CC1=CNC2=C1C=CC=C2)C(N[C@H](C(N([C@H](C(N[C@@H]3C(N[C@@H](CC4CCN(CC(O)=O)CC4)C(N[C@@H](CC(N)=O)C(N[C@@H](CC5=CC=C6C=CC=CC6=C5)C(N[C@@H](CCCCNC(CN7CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC7)=O)C(N[C@@H](CC(O)=O)C(N[C@H](C(N[C@H](C(N8CCC[C@H]8C(N)=O)=O)CC9=CNC%10=C9C=CC=C%10)=O)CSCSC3)=O)=O)=O)=O)=O)=O)=O)CC(C)(C)C)C)=O)[C@@H](C)O)=O)=O
-
Synonyms
MC339
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvant et solubilité
DMSO : 100 mg/mL (46.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[2]. Ninatti G, et al. Radioligand Therapy in Cancer Management: A Global Perspective. Cancers (Basel). 2025;17(21):3412. Published 2025 Oct 23. [Content Brief]
[3]. Ku SY, et al. Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer. Mol Cancer Ther. 2026;25(2):346-354. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.4668 mL | 2.3338 mL | 4.6676 mL | 11.6689 mL |
| 5 mM | 0.0934 mL | 0.4668 mL | 0.9335 mL | 2.3338 mL | |
| 10 mM | 0.0467 mL | 0.2334 mL | 0.4668 mL | 1.1669 mL | |
| 15 mM | 0.0311 mL | 0.1556 mL | 0.3112 mL | 0.7779 mL | |
| 20 mM | 0.0233 mL | 0.1167 mL | 0.2334 mL | 0.5834 mL | |
| 25 mM | 0.0187 mL | 0.0934 mL | 0.1867 mL | 0.4668 mL | |
| 30 mM | 0.0156 mL | 0.0778 mL | 0.1556 mL | 0.3890 mL | |
| 40 mM | 0.0117 mL | 0.0583 mL | 0.1167 mL | 0.2917 mL |
ETN029 Related Classifications
HY-W1126504 Related Classifications
Powered by Bioz